Two papers published in 2026 used the same animal model — the obese ZSF1 rat, the workhorse model of heart failure with preserved ejection fraction (HFpEF) — and the same drug, SS-31. One looked at the heart. One looked at skeletal muscle. They reached almost opposite conclusions, and the split says something useful about how to read SS-31 (elamipretide) research generally.

This piece covers what those two studies actually measured, why "mitochondria improved" is not the same claim as "the organ worked better", and what the SS-31 Australia regulatory picture looks like right now. If you want the compound's background first, the SS-31 profile covers structure, mechanism and history.

What is SS-31 and why cardiolipin keeps coming up

SS-31 is a small synthetic tetrapeptide, also known as elamipretide, MTP-131 and (historically) Bendavia. Its proposed mechanism is not receptor agonism. It accumulates in the inner mitochondrial membrane and associates with cardiolipin, an anionic phospholipid concentrated there, where it is thought to stabilise cristae architecture and support oxidative phosphorylation. Work published in the Journal of Biological Chemistry argued the effect is better described as SS-31 binding anionic lipid bilayers and modulating membrane surface electrostatics, with the magnitude scaling to anionic lipid content rather than depending on a discrete binding pocket — and, notably, uptake that does not require an intact membrane potential, which is why it can in principle reach already-sick mitochondria.

That mechanism is the most solid part of the SS-31 story. The harder question is whether fixing mitochondrial bioenergetics changes what a patient or an animal can actually do.

The heart study: bioenergetics up, function flat

Schauer and colleagues, publishing in the International Journal of Molecular Sciences in January 2026, gave female obese ZSF1 rats vehicle or elamipretide for 12 weeks, with age-matched lean rats as controls, then assessed cardiac mitochondrial function, mitochondrial structure and cardiovascular performance.

The title is the finding: mitochondrial targeting improved myocardial bioenergetics without translating into functional benefit. Complex I/II-linked respiration rose modestly. Diastolic performance and mechanical indices did not improve. The authors' interpretation is that once HFpEF is established, hypertrophy- and fibrosis-linked remodelling dominates, and the functional effects of elamipretide are insufficient to reverse the structural and compositional mitochondrial defects already present.

That is a negative result on the endpoint that matters clinically, reported in a rat.

The skeletal muscle study: the same model, a different answer

A second 2026 study in the same HFpEF rat model looked at limb muscle instead of myocardium. Untreated HFpEF rats showed reduced cardiolipin content and impaired cardiolipin maturation, contractile dysfunction, titin hyperphosphorylation, fibre atrophy and raised oxidative stress markers.

Elamipretide improved whole-muscle contractile function — soleus +8.2%, extensor digitorum longus +10.9% — with much larger effects at the single-fibre level (soleus +173.2%, EDL +66.0%). It reduced titin phosphorylation (soleus −35.4%, EDL −40.2%) and prevented atrophy (soleus +49%, EDL +54.8%). The authors positioned cardiolipin stabilisation as a modulator of both mitochondrial and contractile function.

Two caveats before anyone extrapolates. First, these are rats, single studies, not replicated independently. Second, the gap between +8-11% whole-muscle force and +66-173% single-fibre force is a reminder that the size of a preclinical effect depends heavily on the preparation you measure it in — isolated fibres remove the connective tissue, perfusion and neural drive that limit intact muscle. The percentage that travels furthest on social media is usually the one measured furthest from a whole organism.

Why the split matches SS-31's human record

Read together, the two rat papers describe a compound that does more for skeletal muscle than for a remodelled heart. The human record so far points the same way.

The only approval SS-31 has anywhere is the FDA's accelerated approval of Forzinity (elamipretide) on 19 September 2025, for Barth syndrome in patients weighing at least 30 kg — granted after an earlier complete response letter. The indication is specifically "to improve muscle strength", and the FDA label states it rests on an improvement in knee extensor muscle strength, an intermediate clinical endpoint, with continued approval contingent on verification of clinical benefit in a confirmatory trial. The label also notes the increase was not seen during the randomised portion of the trial; it emerged in the open-label extension, where 8 patients continued to week 168.

Meanwhile the phase 3 programme in primary mitochondrial myopathy — a broader, larger indication — missed both of its endpoints. Barth syndrome is a disorder of cardiolipin metabolism and includes cardiomyopathy, yet the approved claim is a skeletal muscle strength claim, not a cardiac one. The 2026 rat data are consistent with that pattern rather than contradicting it.

None of this makes SS-31 useless. It makes the plausible benefit narrower and more organ-specific than the "mitochondrial rejuvenation" framing found in consumer peptide marketing.

Is SS-31 legal in Australia? The regulatory position

Forzinity is a US approval. Elamipretide is not on the Australian Register of Therapeutic Goods (ARTG), so there is no TGA-approved elamipretide product in Australia for Barth syndrome or anything else. In practical regulatory terms it is an unapproved therapeutic good here.

That matters in two ways:

  • Access. Unapproved goods can only be supplied through defined TGA pathways — the Special Access Scheme, the Authorised Prescriber scheme, or a clinical trial — and those pathways are initiated by a registered health practitioner, not by a consumer. They also require other ARTG-listed options to have been considered.
  • Quality. Material sold online as "SS-31 for research" sits outside TGA assessment for safety, quality and efficacy entirely. Identity, purity and sterility are unverified by any Australian regulator. A US approval for one ultra-rare genetic disease does not transfer any assurance to an unapproved vial.

We don't cover sourcing. For how other compounds sit against Australian regulation, see the peptides library.

Want new SS-31 and mitochondrial peptide findings summarised as they publish, with the study size and species stated up front? Join the free updates list.

What would actually move this forward

Three things, in order of usefulness:

  1. The confirmatory trial. Accelerated approval is provisional by design. Verification of clinical benefit in Barth syndrome is the single highest-value dataset in the SS-31 pipeline.
  2. Independent replication of the muscle result. One group, one rat strain, one drug window is a hypothesis, not a finding.
  3. A cardiac endpoint that moves. The 2026 HFpEF heart paper is the latest in a line of cardiac work where bioenergetics improve and function doesn't. Until that dissociation breaks, cardiac claims for SS-31 should be treated as unsupported.

FAQ

What is SS-31 (elamipretide) used for?

Its only approved use anywhere is Barth syndrome, under FDA accelerated approval as Forzinity (September 2025), to improve muscle strength in patients weighing at least 30 kg. Every other proposed use — cardiac, ophthalmic, mitochondrial myopathy, anti-ageing — remains investigational, and the phase 3 in primary mitochondrial myopathy missed both endpoints.

Does SS-31 research show it improves heart function?

Not so far. A January 2026 study in obese ZSF1 HFpEF rats found elamipretide modestly increased mitochondrial respiration in the heart without improving diastolic performance or mechanical indices, and no human cardiac approval exists.

Is SS-31 legal in Australia?

Elamipretide is not on the ARTG, so there is no TGA-approved product in Australia. It would be an unapproved therapeutic good, accessible only via a practitioner-initiated pathway such as the Special Access Scheme, Authorised Prescriber scheme or a clinical trial.

How strong is the SS-31 muscle evidence?

A 2026 rat study reported improved contractile function in soleus (+8.2%) and EDL (+10.9%) whole muscle, with much larger single-fibre effects. It is a single unreplicated animal study, and the isolated-fibre numbers are not a guide to what whole organisms would do.

Sources

Not medical advice. retatrutide.net.au is independent and does not sell or source peptides. Elamipretide holds US accelerated approval for Barth syndrome only and is not on the ARTG; all other uses discussed here are investigational.